GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (OTCPK:AAVXF) » Definitions » Accounts Payable & Accrued Expense for Financial Companies

Abivax (Abivax) Accounts Payable & Accrued Expense for Financial Companies


View and export this data going back to 2016. Start your Free Trial

What is Abivax Accounts Payable & Accrued Expense for Financial Companies?

Accounts Payable & Accrued Expense for Financial Companies only applies to insurance companies.


Abivax (Abivax) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (OTCPK:AAVXF) » Definitions » Accounts Payable & Accrued Expense for Financial Companies
Traded in Other Exchanges
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based biotechnology company. It is focused on using antiviral technology platforms targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein in the nucleus or the cytoplasm of the infected cell during viral infection, the Immune stimulation platform focuses on invariant natural killer agonists and the Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma.